Establishment of the Human Intestinal and Salivary Microbiota Biobank - Oncologic Diseases

Non Small Cell Lung Cancer Clinical Trial

— BIOMIS-Onco  

Official title:

Costituzione Della Biobanca Del Microbiota Intestinale e Salivare Umano: Dalla Disbiosi Alla Simbiosi

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04698161
• Other study ID #: BIOMIS-Onco
• Status: Completed
• Start date: February 25, 2021
• Est. completion date: July 11, 2022

Study information

• Verified date: January 2022
• Source: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective, clinical, multicentre study aimed to collect biological samples and study microbiota from subjects with non-small-cell lung cancer (NSCLC) and metastatic melanoma. Microbiota is a complex consortium of microorganisms, located at the mucosal level (in particular intestinal, oral and vaginal) having a key role in human health and in the onset of several diseases. Microbiota alterations have been found in several diseases (gastrointestinal, metabolic, renal, oncological, gynaecological)

The study will allow to:

• Provide biological samples (faeces, saliva, blood, urine) from oncologic patients to the first Italian microbiota biobank;

• Study microorganisms using different in vitro and in vivo techniques;

• Study the link between the microbiota and the disease. This study is part of the BIOMIS project (Project Code: ARS01_01220), presented as part of the "Avviso per la presentazione di progetti di ricerca industriale e sviluppo sperimentale nelle 12 aree di specializzazione individuate dal PNR 2015-2020" and admitted to funding under the National Operational Program "Ricerca e Innovazione" 2014-2020 by directorial decree of MIUR - Department for Higher Education and Research - n. 2298 of 12 September 2018. BIOMIS includes several clinical studies that enrol patients with different pathologies to collect and store biological samples and study microbiota.

Description:

The primary aim of this multicentric study is to populate the first national microbioma biobank with biological samples (fecal, salivary, urinary and blood samples) subjects suffering from selected oncologic diseases, i.e. non-small-cell lung cancer (NSCLC) and metastatic melanoma. The secondary aim is the characterization of microorganisms of the biobank and study of the microbiota-pathology relationship using meta-omics, in vitro and in vivo approaches.

The study plans to enrol 50 subjects at IRCCSS Istituto Tumori di Bari, according to the inclusion/exclusion criteria. The study participation is voluntary, and the subjects have the right to withdraw from the study at any time and for any reason.

During the study, 3 visits are planned:

• Visit 0 (V0), including description of the objectives and procedures study, signature written informed consent, inclusion/exclusion criteria evaluation, medical examination (blood pressure measurement, abdominal and thoracic physical examination), filling in of the anamnestic questionnaire, delivery of the coproculture kit, delivery of kits for the collection of fecal, salivary and urinary material to be reported at Visit 1 and delivery of a 3-day food diary, to be completed autonomously in the days preceding the Visit 1.

• Visit 1 (V1) - delivery of the of the collected biological material (feces, saliva, urine), and of a 3-day food diary, filling in of the new signs and symptoms anamnestic questionnaire and blood sampling by medical staff.

• Telephone evaluation: administration of a "Food Frequency Questionnaire" to assess the subjects' alimentary habits.

Standard Operative Procedures (SOP) for samples storing, transport and processing will be adopted to ensure samples stability and grant results validity and quality.

Following collections, samples will be processed in different aliquots that will be used for:

• routine screening;

• storage in the I.R.C.C.S. - Istituto Tumori "Giovanni Paolo II" human microbiote biobank;

• evaluation of the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile;

• Evaluation of the transcriptomic profile of PBMCs of healthy subjects and subjects affected by selected pathologies and evaluation of the serum proteomic profile Furthermore, molecular characterization of pathogenic microorganisms and pathogenic biotypes (pathovars) of commensal species of subjects with selected pathologies will be conducted.

Part of the biological material will be used for animal studies on the physiopathological role of the human intestinal microbiota transplanted into mouse models of pathology and Germ-free mouse models (specific animal study protocol developed).

Also, in vitro studies on mucosal models to evaluate the interaction between the microbiota and the intestinal mucosa will be conducted.

The study foresees no more than minimal risk associated with blood sampling procedures. All the necessary measures to avoid any risks / inconveniences resulting from participation of the subject under study will be taken.

The study is compliant with Good Clinical Practice. Study protocol and all related documents have been approved by approved by the Independent Ethics Committees (IEC) of the involved clinical sites.

To ensure the protection and confidentiality of the participants' data, all study activities will be carried out in accordance with the European General Data Protection Regulation, Regulation (EU) 2016/679, which repeals Directive 95/46/EC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: July 11, 2022
• Est. primary completion date: July 11, 2022
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

PATIENTS WITH NSLSC

• NSLSC diagnosis

• aged between 18 and 75 years

• omnivorous diet

• having suspended antibiotic therapy for at least 15 days

• cessation of treatment with cortisone for at least 15 days

• signature of the informed consent

PATIENTS WITH METASTATIC MELANOMA

• metastatic melanoma diagnosis

• aged between 18 and 75 years

• omnivorous diet

• having suspended antibiotic therapy for at least 15 days

• cessation of treatment with cortisone for at least 15 days

• signature of the informed consent

Exclusion Criteria:

PATIENTS WITH NSLSC/METASTATIC MELANOMA

Exclusion criteria:

• Current treatment with antibiotics or immunosuppressive drugs Previous chemotherapy treatmment Current or previous infectious diseases (HAV, HBV, HCV, HIV, Cytomegalovirus, Epstein-Barr virus)

• Chronic liver disease

• History of Clostridium difficile infections

• Recent (<3 months) therapy with antibiotics, immunosuppressive drugs, chemotherapy

• Chronic therapy with proton pump inhibitors

• Recent (<3 months) use of probiotics, laxatives or other aids (drugs / supplements) for the regulation of gastrointestinal activity

• Previous history of organ / tissue transplantation

• Recent onset of diarrhea

• Chronic diarrhea

• Chronic constipation

• Previous gastrointestinal surgery (eg gastric bypass)

• Recurring urinary tract infections (3 cases per year)

• Previous major acute cardiovascular diseases (myocardial infarction, stroke)

• Type 2 diabetes mellitus

• Hypertension

• eGFR (estimated glomerular filtration rate) lower than 60ml / minute and / or diagnosis of nephropathy

• Chronic gastrointestinal disorders

• Systemic inflammatory diseases

• Autoimmune disorders or history of chronic and systemic autoimmune disorders

• Neurodegenerative disorders

• Pregnancy and breastfeeding

• Psychiatric conditions that reduce protocol compliance.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Metastatic Melanoma
• Non Small Cell Lung Cancer

Intervention

Other:
• Biological sample collection
Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
• Questionnaire
Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
• Medical examination
Blood pressure measurement, abdominal and thoracic physical examination

Locations

Country	Name	City	State
Italy	IRCCS Istituto Tumori Giovanni Paolo II	Bari

Sponsors (5)

Lead Sponsor	Collaborator
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari	Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, Istituti Tumori Giovanni Paolo II, University of Bari Aldo Moro, University of Salento

Country where clinical trial is conducted

Italy, 

References & Publications (5)

Bingula R, Filaire M, Radosevic-Robin N, Berthon JY, Bernalier-Donadille A, Vasson MP, Thivat E, Kwiatkowski F, Filaire E. Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma: Study protocol for case-control observational trial. Medicine (Baltimore). 2018 Dec;97(50):e13676. doi: 10.1097/MD.0000000000013676. — View Citation

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017 Jun 1;28(6):1368-1379. doi: 10.1093/annonc/mdx108. Erratum in: Ann Oncol. 2019 Dec 1;30(12):2012. — View Citation

Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, Pamer EG, Wolchok JD. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016 Feb 2;7:10391. doi: 10.1038/ncomms10391. — View Citation

Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY. Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients. Neoplasia. 2017 Oct;19(10):848-855. doi: 10.1016/j.neo.2017.08.004. Epub 2017 Sep 15. — View Citation

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 Jan 5;359(6371):104-108. doi: 10.1126/science.aao3290. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biological samples collection for establishment of the first National Microbiome Biobank	Recruitment of 50 subjects (non-small-cell lung cancer and metastatic melanoma patients) to collect biological samples for establishment of the first National Microbiome Biobank	through study completion, an average of 1 year